SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lasa Supergenerics - Quaterly Results

09 Jun 2023 Evaluate
The sales is pegged at Rs. 353.23 millions for the March 2023 quarter. The mentioned figure indicates a decline of about -31.03% as against Rs. 512.12 millions during the year-ago period.The Net Loss for the quarter ended March 2023 is Rs. -150.03 millions as compared to Net Profit of Rs. 121.29 millions of corresponding quarter ended March 2022Operating Profit reported a sharp decline to 52.70 millions from 109.45 millions in the corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202303 202203 % Var 202303 202203 % Var 202303 202203 % Var
Sales 353.23 512.12 -31.03 1295.68 1371.27 -5.51 1295.68 1371.27 -5.51
Other Income 9.31 1.96 375.00 18.05 2.75 556.36 18.05 2.75 556.36
PBIDT 52.70 109.45 -51.85 -47.89 162.72 -129.43 -47.89 162.72 -129.43
Interest 4.15 0.07 5828.57 41.61 0.40 10302.50 41.61 0.40 10302.50
PBDT -150.42 149.81 -200.41 -288.47 83.72 -444.57 -288.47 83.72 -444.57
Depreciation 41.70 36.11 15.48 134.19 145.11 -7.53 134.19 145.11 -7.53
PBT -192.12 113.70 -268.97 -422.66 -61.39 588.48 -422.66 -61.39 588.48
TAX -42.09 -7.59 454.55 -36.45 -8.07 351.67 -36.45 -8.07 351.67
Deferred Tax -42.09 -9.86 326.88 -36.88 -14.55 153.47 -36.88 -14.55 153.47
PAT -150.03 121.29 -223.70 -386.21 -53.32 624.32 -386.21 -53.32 624.32
Equity 501.01 406.73 23.18 501.01 406.73 23.18 501.01 406.73 23.18
PBIDTM(%) 14.92 21.37 -30.19 -3.70 11.87 -131.15 -3.70 11.87 -131.15

Lasa Supergenerics Share Price

8.47 0.33 (4.05%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×